Food ingredients firm Danisco has announced  rise in sales in the first half, but the cost of integrating US based biotechnology company Genencor cut its profits.


Sales for the half, ended 31 October 2005, were DKK10.391bn (US$1.67bn), compared with DKK8.605bn the year before. Profit was DKK545m, compared with DKK727m.


Sales for the second quarter were DKK5.229bn, compared with 4.399bn a year ago, while profit was DKK269m, compared with DKK319m.


The company said it maintained its overall outlook for 2005/06 in spite of rising raw material and energy costs in ingredients and sugar. With 5% organic growth year-to-date the ingredients parts of its business was estimated to have at least maintained its global market share. The same was the case for Genencor with 8% organic growth in the period.


The closure of Genencor’s health care activities has now been completed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genencor contributed much of the rise in sales, but the fall in profit was mainly due to the cost of its consolidation.